

Biosimilars are coming!

None of the industry watchers we spoke with was willing to say which drug maker is poised to lead the US biosimilars market. Some of the pending entrants

COMPANY	BIOSIMILAR OF (INDICATION)
Amgen/Watson via Synthon	Herceptin (cancer)
Eli Lilly	Lantus (diabetes)
Merck	Enbrel (rheumatoid arthritis)
Merck	Granulocyte colony stimulating factor (i.e., Neulasta; supportive cancer care)